Adalimumab-atto
AMJEVITA (adalimumab-atto) is a biosimilar medication to Humira, containing the active ingredient adalimumab, a monoclonal antibody that blocks tumor necrosis factor (TNF) to reduce inflammation. It's administered via subcutaneous injection in strengths like 20 mg/0.4 mL and 40 mg/0.8 mL, used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Manufactured by Amgen Inc., it's a prescription drug approved under BLA761024. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | AMJEVITA (adalimumab-atto) is a biosimilar medication to Humira, containing the active ingredient adalimumab, a monoclonal antibody that blocks tumor necrosis factor (TNF) to reduce inflammation. It's administered via subcutaneous injection in strengths like 20 mg/0.4 mL and 40 mg/0.8 mL, used to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Manufactured by Amgen Inc., it's a prescription drug approved under BLA761024. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Adalimumab-atto",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Adalimumab-atto — ANDA 761024 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761024"
}
]
|
| identifier | ANDA761024 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-safety",
"fda",
"health-care",
"medications"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Adalimumab-atto |
